Recent years have seen a rise in the use of glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1 and gastric inhibitory polypeptide receptor agonists,18 which may have implications for obesity management and potentially influence the prevalence of SLD. Here, GIPR is linked to Obesity.